Abstract
Our aim was to compare Sodium-glucose co-transporter 2 inhibitors (SGLT-2i) to Dipeptidyl peptidase-4 inhibitors (DPP-4i) as add-on therapy to metformin. We searched for randomized trials comparing SGLT-2i to DPP-4i as add-on therapy to metformin in Type 2 diabetes.We pooled trials reporting outcomes between 12 and 26 weeks together while trials reporting results ≥52 weeks were pooled together. The primary outcomes were the change in haemoglobin A1c (A1c) at ≤26 and ≥52 weeks. Sensitivity analyses were performed according to the dose of SGLT-2i and according to baseline A1c for the primary outcomes. Seven trials met our inclusion criteria. There was a statistically significant reduction in A1c at ≥52 weeks favouring SGLT-2i compared to DPP-4i (MD [95% CI]=-0.11% [-0.20, -0.03]) but no significant difference at ≤26 weeks (MD [95% CI]=-0.05% [-0.16, 0.05]). SGLT-2i caused significantly more weight loss compared to DPP-4i at ≤26 weeks and ≥52 weeks (MD [95% CI]=-2.31kg [-2.66, -1.96] and -2.45kg [-2.83, -2.07], respectively). SGLT-2i treated patients had a significantly more genital infection compared to DPP-4i. On restricting the analysis according to the SGLT-2i FDA-approved dose, only higher doses at ≥52 weeks showed a statisti...Continue Reading
Citations
Feb 16, 2019·British Journal of Clinical Pharmacology·Arintaya PhrommintikulNipon Chattipakorn
Jun 1, 2019·Expert Opinion on Drug Safety·Elizabeth Mary LamosStephen N Davis
Jun 7, 2019·Diabetes, Obesity & Metabolism·Basem M MishrikyDoyle M Cummings
Feb 2, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Awadhesh Kumar SinghViswanathan Mohan
Feb 14, 2020·Cardiovascular Diabetology·Shih-Chieh ShaoEdward Chia-Cheng Lai
May 13, 2020·Journal of Clinical Pharmacology·Jarrod L UhrigDoyle M Cummings
Jan 14, 2020·Endocrine·Suhui QieGuoqiang Liu
Jun 24, 2020·Annals of Surgical Oncology·Takehiko Yokobori
Aug 22, 2020·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·André J Scheen
May 10, 2020·Diabetes, Obesity & Metabolism·Anat FisherUNKNOWN Canadian Network for Observational Drug Effect Studies (CNODES) Investigators
Dec 19, 2020·Chronic Diseases and Translational Medicine·Fan YangDa-Long Zhu
Jun 18, 2021·European Journal of Preventive Cardiology·Siwen WangMeichun Deng
Aug 3, 2021·International Journal of General Medicine·Awadhesh K SinghPartha Pratim Chakraborty
May 12, 2021·Aging·Xianzhi LiLin Liao
Jun 19, 2021·Diabetes, Obesity & Metabolism·Gustavo A AugustoTamara Melnik